Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 45 Show results per page	View Search Criteria \| Help With Results

Last Modified: 8/23/2006 First Published: 4/1/2001


1.		Phase I/II Study of Immunization With In Vitro-Treated Autologous Tumor Cells and Dendritic Cells With Sargramostim (GM-CSF) in Patients With Stage III or IV or Recurrent Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				Other				HOAG-VACCINE-RN NCI-V01-1647, NCT00014131

Last Modified: 8/6/2008 First Published: 9/1/2002


2.		Phase I/II Randomized Study of Vaccination With Melanoma Antigen-Pulsed Dendritic Cells Versus Melanoma Antigens With QS21 Adjuvant in Patients With Surgically Resected Stage IIB, IIC, or III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NYU-RUH-NBH-0428-0401 RUH-NBH-0428-0401, NCI-5636, NCT00045383, 5636

Last Modified: 6/7/2006 First Published: 2/21/2003


3.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				over 18				Other				ERLANGEN-ONTAK EU-20246, NCT00056134

Last Modified: 6/27/2007 First Published: 11/20/2003


4.		Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				ERLANGEN-DERMA-ER-DC-06 EU-20317, NCT00074230

Last Modified: 9/19/2007 First Published: 4/7/2006


5.		Phase I/II Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				NCI				MCC-13649 LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508


6.		Study Testing the Biologic Activity and Safety of a Vaccine in Patients With Newly Diagnosed Stage IV Kidney Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				AGS-003-004 Bukowski-8077, Logan-0506-05, Drabkin-05-0167, White-04-05-01A, Figlin-05-03-099-01, NCT00272649


7.		The Role of Peptide-Loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				pepDCIL2- HMO-CTIL NCT00279058


8.		Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				immatureDC- HMO-CTIL NCT00278018


9.		Combined Modality Treatment for Patients With Stage IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				21 to 75				Other				Baylor IRB #006-025-01 0000, NCT00313235


10.		Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				RDA-0537 NCT00345293

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute